Fasinumab

Fasinumab is a human monoclonal antibody designed for the treatment of acute sciatic pain.[1][2]

Fasinumab
Monoclonal antibody
Type?
SourceHuman
TargetHNGF
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
KEGG
Chemical and physical data
FormulaC6406H9896N1700O2026S46
Molar mass144.6 kg/mol g·mol−1

This drug was developed in collaboration by Teva Pharmaceutical Industries and Regeneron Pharmaceuticals.

It is currently at Phase III trials.

See also

References


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.